

ASX Announcement 21 August 2017

Boardroom Media Interview

ITL Health Group is pleased to provide the opportunity to listen to an audio interview with Mr Bill Mobbs, Executive Chairman, following the release of the Company's Full Year Results today.

In the interview Mr Mobbs covers:

- The strong Full Year Results
- An update on the \$3.3bn Blood Culture Testing Market
- The positive year forecast for MyHealthTest
- The exciting 12 months ahead for the Group

Click link for full interview:

https://boardroom.media/broadcast/?eid=5996888a182f6a5a0dbc28e0&p= c35fe15cf269d7c70462d60d32c45931

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the AFR Innovative Companies Awards

Australian Securities Exchange Code: ITD

Ordinary Shares 96,850,348

Board of Directors

Bill Mobbs Mark Peatey Andrew Turnbull Executive Chairman Non-executive Director Non-executive Director

Trevor Doolan

Chief Financial Officer & Company Secretary

ITL Contact

Trevor Doolan Phone: Email: Address Company Secretary +61 3 8773 3050 info@itl-limited.com Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

www.itlhealthgroup.com

Media

 Walbrook IR
 Ben Knowles

 Phone:
 +61 426 277 760

 Email:
 ben.knowles@walbrookir.com.au